| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
ORIGINAL ARTICLE |
1 Institute of Pathology, Charité University Hospital, D-10117 Berlin, Germany
2 Tumour Centre, Charité University Hospital
Correspondence to:
Dr G Kristiansen
Institute of Pathology, Charité Hospital, Campus Mitte, Schumannstr. 20/21, D-10117 Berlin, Germany; glen.kristiansen{at}charite.de
Background: Activated leucocyte cell adhesion molecule (ALCAM) has been implicated in tumorigenesis and tumour progression of malignant melanoma and prostate cancer.
Aims: To clarify the expression patterns of ALCAM in colon cancer and to correlate these with clinicopathological parameters, including patient survival.
Methods: One hundred and eleven colorectal carcinomas were immunostained for ALCAM (clone MOG/07) using a standard detection system. Cytoplasmic and membranous immunoreactivity were scored semiquantitatively. Fisher’s exact test, 
2 test for trends, Kaplan–Meier analysis, and Cox’s regression were applied.
Results: In colorectal cancer, 58.6% and 30.6% of cases showed strong cytoplasmic and membranous expression of ALCAM, respectively. No significant correlation with patient age, tumour grade, stage, or nodal status was apparent. In survival analyses, membranous ALCAM expression correlated significantly (Cox’s regression, p = 0.028; relative risk, 2.3) with shortened patient survival.
Conclusions: ALCAM is frequently upregulated in colorectal cancer and is a new independent prognostic marker, underscoring the importance of ALCAM in tumour progression in this disease.
Abbreviations: ALCAM, activated leucocyte cell adhesion molecule; WHO, World Health Organisation
Keywords: colon cancer; activated leucocyte cell adhesion molecule ALCAM; CD166; immunohistochemistry; prognosis
This article has been cited by other articles:
|
|
 |
|
  J. W.J. van Kilsdonk, R. H. Wilting, M. Bergers, G. N.P. van Muijen, J. Schalkwijk, L. C.L.T. van Kempen, and G. W.M. Swart Attenuation of Melanoma Invasion by a Secreted Variant of Activated Leukocyte Cell Adhesion Molecule Cancer Res., May 15, 2008; 68(10): 3671 - 3679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Ricci-Vitiani, A Pagliuca, E Palio, A Zeuner, and R De Maria Colon cancer stem cells Gut, April 1, 2008; 57(4): 538 - 548. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mezzanzanica, M. Fabbi, M. Bagnoli, S. Staurengo, M. Losa, E. Balladore, P. Alberti, L. Lusa, A. Ditto, S. Ferrini, et al. Subcellular Localization of Activated Leukocyte Cell Adhesion Molecule Is a Molecular Predictor of Survival in Ovarian Carcinoma Patients Clin. Cancer Res., March 15, 2008; 14(6): 1726 - 1733. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. te Riet, A. W. Zimmerman, A. Cambi, B. Joosten, S. Speller, R. Torensma, F. N. van Leeuwen, C. G. Figdor, and F. de Lange Distinct kinetic and mechanical properties govern ALCAM-mediated interactions as shown by single-molecule force spectroscopy J. Cell Sci., November 15, 2007; 120(22): 3965 - 3976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dalerba, S. J. Dylla, I.-K. Park, R. Liu, X. Wang, R. W. Cho, T. Hoey, A. Gurney, E. H. Huang, D. M. Simeone, et al. Phenotypic characterization of human colorectal cancer stem cells PNAS, June 12, 2007; 104(24): 10158 - 10163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kobayashi, H. Kubo, T. Suzuki, K. Ishizawa, M. Yamada, M. He, Y. Yamamoto, H. Yamamoto, H. Sasano, H. Sasaki, et al. Endogenous Secretory Receptor for Advanced Glycation End Products in Non-Small Cell Lung Carcinoma Am. J. Respir. Crit. Care Med., January 15, 2007; 175(2): 184 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhang, A. Y. Liu, P. Loriaux, B. Wollscheid, Y. Zhou, J. D. Watts, and R. Aebersold Mass Spectrometric Detection of Tissue Proteins in Plasma Mol. Cell. Proteomics, January 1, 2007; 6(1): 64 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kato, Y. Tanaka, M. Hayashi, K. Okawa, and N. Minato Involvement of CD166 in the Activation of Human {gamma}{delta}T Cells by Tumor Cells Sensitized with Nonpeptide Antigens J. Immunol., July 15, 2006; 177(2): 877 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Burkhardt, E Mayordomo, K-J Winzer, F Fritzsche, T Gansukh, S Pahl, W Weichert, C Denkert, H Guski, M Dietel, et al. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer J. Clin. Pathol., April 1, 2006; 59(4): 403 - 409. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |
